Phase I clinical trial of 17-allylamino-17-demethoxy-geldanamycin (KOS-953) [tanespimycin] in combination with bortezomib [Velcade] in patients with relapsed and relapsed/refractory multiple myeloma

Next Previous
Trial Profile

Phase I clinical trial of 17-allylamino-17-demethoxy-geldanamycin (KOS-953) [tanespimycin] in combination with bortezomib [Velcade] in patients with relapsed and relapsed/refractory multiple myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2007

At a glance

  • Drugs Bortezomib; Tanespimycin
  • Indications Multiple myeloma
  • Focus Adverse reactions

    • Most Recent Events

    • 18 Jan 2007 Interim results have been reported.
    • 18 Jan 2007 Status change
    • 04 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top